Media Room

Welcome to CFN’s Media Room

Canadian Frailty Network is Canada’s network for older adults living with frailty. We facilitate evidence-based research, knowledge sharing and clinical practices that improve care for older Canadians living with frailty, and support their families and caregivers.

Canadian Frailty Network is your source of experts on a wide variety of topics relating to health and social care for older adults living with frailty.

For a quick response, please contact:

Kate Cooke, Manager, Communications

Email: info@cfn-nce.ca

Text: (613) 888-0315

Our Most Recent Release

Kingston – July 10, 2019 –CFN has partnered with the Canadian Longitudinal Study on Aging (CLSA), the McMaster Institute for Research on Aging (MIRA), and Metabolon, Inc. to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.  En français.

This collaboration will perform large-scale metabolomic profiling and biomarker identification on samples from Canada’s largest and most comprehensive study on aging (CLSA).

Metabolomics is the process of measuring small molecules in blood and tissues, which can help scientists and clinicians identify biomarkers for diseases or health conditions, such as frailty.

The partnership brings together leaders in research on frailty, metabolomics and aging:

  • Canadian Frailty Network (CFN), Canada’s sole network devoted to improving care for older Canadians living with frailty and their families;
  • The Canadian Longitudinal Study on Aging, a national research platform on aging involving 50,000 men and women in Canada;
  • The McMaster Institute for Research on Aging (MIRA) at McMaster University, which seeks to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations; and
  • Metabolon Inc., the global leader in revealing new biological insights through metabolomics.

In total, 10,000 blood samples collected from participants in the CLSA will be analyzed for both metabolomic and inflammatory biomarkers linked to frailty. Two additional biomarkers linked to aging will be analyzed from blood samples provided by 30,000 participants.

“CFN’s mission is to improve care for older Canadians to avoid or live with frailty,” said John Muscedere, MD, scientific director of Canadian Frailty Network and a professor of critical care medicine at Queen’s University/Kingston Health Sciences Centre. “Our work is based on creating scientific evidence that can be translated into practices and policies to avoid or delay frailty. We have built the largest and most comprehensive research portfolio and knowledge base on frailty that has ever existed in Canada.”

To date there has been little consensus on the biological mechanisms underpinning frailty. Analysis of the CLSA samples will allow researchers to identify metabolites that will help to improve not only early prediction of frailty, but also lead to further research on treatments addressing specific aspects of frailty.

“By enhancing the Canadian Longitudinal Study on Aging with data on frailty biomarkers, researchers will be able to ask questions not only about the basic science of frailty, but how that ties into the physical, psychological and social impacts of being frail,” said Parminder Raina, PhD, professor in the Department of Health Research Methods, Evidence and Impact at McMaster University, lead principal investigator of the CLSA and scientific director of MIRA.

“We know, from our nearly 20 years of experience conducting more than 10,000 studies, that metabolomics can enable biological discoveries that are otherwise unseen through other more established technologies,” said Rohan F. Hastie, PhD, president and CEO of Metabolon.

“By combining the detailed clinical and lifestyle information that is unique to the CLSA, with analytical power of Metabolon’s global metabolomics platform, this partnership will enable deeper understanding of disease etiology and progression across a wide range of conditions. It is an honor to be chosen by the CLSA to perform this important work.”

Specifically, the program will develop a research platform to understand the influence of the metabolome, microbiome, genes, diet, lifestyle and drug treatments on the health and well-being of aging populations.

“As a leader in mobility and frailty research, the McMaster Institute for Research on Aging is a proud contributor to this important research partnership that will help to improve understanding and mitigate the risks and consequences of frailty,” said Ine Wauben, managing director of the McMaster Institute for Research on Aging and the CLSA.

More than one million older Canadians are medically frail. This translates to over 25 per cent of Canadians between the ages of 65–84 years, and over 50 per cent over the age of 85.  By 2025, it is estimated that more than two million Canadians will be living with frailty. Frailty also impacts family and friend caregivers and places large burdens on health and social care systems to meet the growing demand.

– 30 –

Media inquiries:

Kate Cooke, Communications Manager, Canadian Frailty Network, Tel: 613-549-6666, x.2834; Mobile: 613-888-0315, kate@cfn-nce.ca

Laura Lawson, Communications Manager, Canadian Longitudinal Study on Aging, Tel: 905-525-9140, ext. 21413; Mobile: 905-921-3034; llawson@mcmaster.ca

Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: 954-461-7648, eromero@metabolon.com

 

 About the Partners

Canadian Frailty Network (CFN) is Canada’s sole network devoted to improving care for older Canadians living with frailty and supporting their families and caregivers. We do this by increasing frailty recognition and assessment, increasing evidence for decision-making from the bedside to the policy making level, advancing evidence-based changes to care, training the next generation of care professionals and scientists, and engaging with older adults and caregivers. Canadian Frailty Network is funded by the Government of Canada’s Networks of Centres of Excellence (NCE) program. For more information: please visit www.cfn-nce.ca, or follow us on Twitter, LinkedIn, or Facebook.

The Canadian Longitudinal Study on Aging (CLSA) is a large, national research platform on health and aging allowing researchers to answer critical questions on the biological, medical, psychological, social, lifestyle and economic aspects of aging, disability and disease. The CLSA follows 51,338 men and women who were between the ages of 45 and 85 at recruitment, for 20 years. Through its large sample, detailed data collection and longitudinal design, the CLSA enables research on the complex interplay among health determinants. For more information: please visit http://www.clsa-elcv.ca/, or follow us on Twitter, LinkedIn, or Facebook.

The McMaster Institute for Research on Aging (MIRA) aims to optimize the longevity of Canada’s aging population through research, education, and collaboration. Interdisciplinary teams work alongside older adults and key stakeholders to find ways that will help Canadians spend more years living well. MIRA also acts as a robust entry point to some of McMaster’s existing research platforms in aging, including the newly formed Collaborative for Health & Aging, the Labarge Centre for Mobility in Aging and the McMaster Optimal Aging Portal. For more information: please visit https://mira.mcmaster.ca/, or follow us on Twitter, LinkedIn, or Facebook.

Metabolon, Inc. is the world’s leading biotechnology company focused on advancing metabolomics. Our AI-driven Precision Metabolomics™ platform detects thousands of biologically important molecules and gives unprecedented insights into health and underlying biological function to drive advances in precision medicine, biomarker discovery, diagnostic testing, and population health initiatives. Metabolon’s expertise also accelerates research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. The company was founded in 2000, is based in Research Triangle Park, North Carolina and has additional operations in Potsdam, Germany. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.

Our Spokespeople

CFN has a roster of internationally renowned experts available for media comments or interviews, or speaking engagements, on topics relating to older adults and frailty.

Russell Williams is Chair of the CFN Board of Directors, and the Senior Vice-President, Mission at Canadian Diabetes Association, and the former President of Innovative Medicines Canada (formerly Rx&D).

John Muscedere is the CFN Scientific Director and Member of the Board of Directors, a critical care physician at Kingston General Hospital and Professor in the Critical Care Department in the School of Medicine at Queen’s University.

Tom Noseworthy is a Member of the CFN Board of Directors, and President and CEO of British Columbia Academic Health Science Network (BC AHSN). He is also a professor of health policy and management at University of Calgary’s Department of Community Health Sciences and Institute for Public Health.

Many of our researchers may also be available on specific topics.

Resources for your use

December 4, 2018 — FREDERICTON – Canadian Frailty Network and the New Brunswick Health Research Foundation (NBHRF) announce projects funded

New Brunswick has Canada’s highest concentration of citizens over 65. NBHRF and CFN introduced the CFN-NBHRF Frailty and Aging Research Engagement (FARE) initiative to address the needs of these vulnerable New Brunswickers.  This fund is used to pursue research and knowledge translation in the area of older adults living with frailty. The latest projects funded address issues often experienced by older adults living with frailty: hospital-to-home transitions, the social effects of moving to assisted living, home support following surgery, and retaining mobility. En français.

September 24, 2018, TORONTO: Frailty impacting more than 1 million Canadians: Consensus needed to measure common condition

More than 1 million Canadians are living with frailty, but a lack of consistent measurement of the condition is potentially exposing patients to inappropriate care, according to a new report from the National Institute on Ageing (NIA), Ryerson University, commissioned by the Canadian Frailty Network (CFN). We Can’t Address What We Don’t Measure Consistently: Building Consensus on Frailty in Canada is authored by Dr. Samir Sinha, Dr. John Muscedere (CFN), Allan McKee, Ivy Wong, Julie Dunning, and Michael Nicin. Click here to read more, or download the report.

September 21, 2018 — TORONTO: Winner of first-ever national innovation showcase dedicated to frailty in older adults announced by Canadian Frailty Network

An Edmonton-based community program designed to transform primary care into a central hubhas been selected as the best innovation of 2018 from more than 80 entries from every region in Canada. The winning project from the Edmonton Oliver Primary Care Network– The Seniors’ Community Hub — was co-created by Dr. Marjan Abbasi (project lead) and Dr. Sheny Khera to better meet the dynamic health and social needs of older adults living with frailty and their family/friend caregivers. CFN created the FRAILTY MATTERS Innovation Showcase to put the spotlight on Canada’s best and identify new approaches that can be scaled up so that all Canadians can benefit. Click here to read more.